US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Medicus Pharma Ltd.

2.60

-0.1900-6.81%

Post-market: 2.610.0100+0.38%19:58 EDT

Volume:135.40K

Turnover:358.43K

Market Cap:41.17M

PE:- -

High:2.78

Open:2.72

Low:2.55

Close:2.79

Loading ...

Overview Company News Filings

Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction

Medicus Pharma Ltd’s Promising Clinical Developments and Strategic Expansion Drive Buy Rating

Medicus Pharma Is Maintained at Buy by D. Boral Capital

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Medicus Pharma Initiated at Buy by D. Boral Capital

Medicus Pharma Secures $4.2 Million for Innovative Skin Treatment Trials

Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering

Medicus Pharma Ltd: Promising Phase 2 Results and Market Potential Drive Buy Rating

Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

BRIEF-Medicus Pharma Announces Positively Trending Interim Analysis For SKNJCT-003 Phase 2 Clinical Study

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for Sknjct-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (Bcc)

THOMSON REUTERS

Medicus Pharma: Plans to Submit Analysis to FDA Under Package Seeking Type C Meeting With FDA in Q2

THOMSON REUTERS

Medicus Pharma Ltd: D-Mna Was Well Tolerated for Both Dose Levels

THOMSON REUTERS

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Wall Street Set to Open Higher Friday as Inflation Data Meets Expectations

MT Newswires Live

US Stock Futures Rise as Investors Await Key Inflation Data

MT Newswires Live

Medicus Pharma submits Phase 2 carcinoma clinical design in UAE

Medicus Pharma Advances Non-Invasive Skin Cancer Treatment in UAE

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (Sknjct-004) to United Arab Emirates (UAE) Department of Health (Doh) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (Bcc)

THOMSON REUTERS

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":2.6,"timestamp":1749844800000,"preClose":2.79,"halted":0,"volume":135397,"hourTrading":{"tag":"盘后","latestPrice":2.61,"preClose":2.6,"latestTime":"19:58 EDT","volume":2249,"amount":5866.0827,"timestamp":1749859131621},"delay":0,"floatShares":6964800,"shares":15832737,"eps":0,"marketStatus":"Market Closed","change":-0.19,"latestTime":"06-13 16:00:00 EDT","open":2.72,"high":2.775,"low":2.55,"amount":358430.114441,"amplitude":0.080645,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":2.79,"preHourTrading":{"tag":"盘前","latestPrice":2.72,"preClose":2.79,"latestTime":"09:29 EDT","volume":1139,"amount":3133.0749777,"timestamp":1749821346303},"postHourTrading":{"tag":"盘后","latestPrice":2.61,"preClose":2.6,"latestTime":"19:58 EDT","volume":2249,"amount":5866.0827,"timestamp":1749859131621},"volumeRatio":0.44699434202464},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":6964800,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.44699434202464,"shares":15832737,"dividePrice":0,"high":2.775,"amplitude":0.080645,"preClose":2.79,"low":2.55,"week52Low":1.8,"pbRate":"--","week52High":8.94,"institutionHeld":0,"latestPrice":2.6,"eps":0,"divideRate":0,"volume":135397,"delay":0,"ttmEps":0,"open":2.72,"prevYearClose":2.43,"prevWeekClose":2.76,"prevMonthClose":2.55,"prevQuarterClose":3.72,"fiveDayClose":2.76,"twentyDayClose":5.95,"sixtyDayClose":3.11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530447040","title":"Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2530447040","media":"Newsfile","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530447040?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:30","pubTimestamp":1745839800,"startTime":"0","endTime":"0","summary":"Antev Shareholders to Receive Aggregate ~19% Equity Stake in Medicus, Plus US$65 Million in Contingent Payments. Antev is developing Teverelix, A next generation GnRH Antagonist, as first in class market product for Acute Urinary Retention  and high CV risk Prostate Cancer. Philadelphia, Pennsylvania-- - Medicus Pharma Ltd.   and Antev Ltd. , a UK-based late clinical-stage drug development company, announced today that they have entered into a binding letter of intent dated April 26, 2025  pursuant to which Medicus has agreed to acquire all of the issued and outstanding shares of Antev  on a share exchange basis .Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention  episodes due to enlarged prostate.Subject to the assumptions, qualifications, and conditions noted in the Letter Agreement, Medicus will negotiate an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/medicus-pharma-ltd-announces-binding-113000145.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medicus-pharma-ltd-announces-binding-113000145.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0077335932.USD","BK4165","BK4192","LU2236285917.USD","LU1366192091.USD","LU1496350171.SGD","LU2237443549.SGD","APC","LU2417539215.USD","LU2237443978.SGD","BK4139","LU2237443622.USD","LU2237443382.USD","MDCX","BPH","AUR","ADT","MDCXW","LU2456880835.USD","LU2420271590.USD","BK4137","BK4156","LU1366333091.USD","LU0157215616.USD","BK4023"],"gpt_icon":0},{"id":"2529346395","title":"Medicus Pharma Ltd’s Promising Clinical Developments and Strategic Expansion Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2529346395","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529346395?lang=en_us&edition=fundamental","pubTime":"2025-04-23 00:35","pubTimestamp":1745339712,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd (MDCX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarth...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltds-promising-clinical-developments-and-strategic-expansion-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltds-promising-clinical-developments-and-strategic-expansion-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX"],"gpt_icon":0},{"id":"2529618805","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2529618805","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529618805?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:27","pubTimestamp":1745238420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 21, 2025 08:27 ET (12:27 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2529703568","title":"Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529703568","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529703568?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:30","pubTimestamp":1745235000,"startTime":"0","endTime":"0","summary":"The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty  to Ninety .The Company to Expand the Study into Additional Trial Sites in Europe. The phase 2 clinical study  which is currently underway in nine  clinical sites in United States will expand into additional sites in United States, as well as two clinical trial sites in Europe.The Company also announced that it has randomized more the forty-five  participants in the study and is on track to submit the package seeking a Type C meeting with the United States Food and Drug Administration  before the end of Q2 2025.The high-dose, 200μg D-MNA, in the study is the maximum dose that was used in the Company's Phase 1 safety and tolerability study  completed in March 2021.SKNJCT-001 met its primary objective of safety and tolerability. The investigational product, D-MNA, was well tolerated across all dose levels in all 13 participants enrolled in the study, with no dose-lim","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/medicus-pharma-provides-sknjct-003-113000635.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medicus-pharma-provides-sknjct-003-113000635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDCXW","BK4104","BK4139","BCC","MDCX","UAE","BK4567"],"gpt_icon":0},{"id":"2527156220","title":"Medicus Pharma Initiated at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2527156220","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527156220?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:34","pubTimestamp":1744630440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2025 07:34 ET (11:34 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2518970785","title":"Medicus Pharma Secures $4.2 Million for Innovative Skin Treatment Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2518970785","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518970785?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:43","pubTimestamp":1741639421,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd ( ($MDCX) ) just unveiled an announcement. Medicus Pharma Ltd. has successfully closed a $4.2 million Tier II Regulation A offer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-secures-4-2-million-for-innovative-skin-treatment-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-secures-4-2-million-for-innovative-skin-treatment-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2518278856","title":"Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278856","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518278856?lang=en_us&edition=fundamental","pubTime":"2025-03-11 04:05","pubTimestamp":1741637100,"startTime":"0","endTime":"0","summary":"Philadelphia, Pennsylvania-- - Medicus Pharma Ltd.   today announced the closing of its previously announced Tier II Regulation A offering of 1,490,000 units, on a \"best-efforts\" basis, at a price of $2.80 per unit. Each unit consisted of one common share of the Company and one warrant to purchase one common share. The warrants have an exercise price of $2.80 per share and will expire 5 years from the date of issuance.The common shares are listed on The Nasdaq Capital Market under the symbol \"MDCX\". The warrants will not trade on any securities exchange.SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/medicus-pharma-ltd-announces-closing-200500644.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medicus-pharma-ltd-announces-closing-200500644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDCX","BK4139","MDCXW"],"gpt_icon":0},{"id":"2517581894","title":"Medicus Pharma Ltd: Promising Phase 2 Results and Market Potential Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517581894","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517581894?lang=en_us&edition=fundamental","pubTime":"2025-03-08 00:25","pubTimestamp":1741364753,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd (MDCX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarth...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltd-promising-phase-2-results-and-market-potential-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/medicus-pharma-ltd-promising-phase-2-results-and-market-potential-drive-buy-rating?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MDCX"],"gpt_icon":0},{"id":"2517914645","title":"Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2517914645","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517914645?lang=en_us&edition=fundamental","pubTime":"2025-03-07 09:30","pubTimestamp":1741311000,"startTime":"0","endTime":"0","summary":"Philadelphia, Pennsylvania-- - Medicus Pharma Ltd.   today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, on a \"best-efforts\" basis, at a price of $2.80 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share. The warrants will have an exercise price of $2.80 per share and will expire 5 years from the date of issuance.The common shares are listed on The Nasdaq Capital Market under the symbol \"MDCX\". The warrants will not trade on any securities exchange. The offering is expected to close on March 10, 2025, subject to customary closing conditions.SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & toler","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/medicus-pharma-ltd-announces-pricing-013000820.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medicus-pharma-ltd-announces-pricing-013000820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MDCXW","BK4139","MDCX"],"gpt_icon":0},{"id":"2517151082","title":"BRIEF-Medicus Pharma Announces Positively Trending Interim Analysis For SKNJCT-003 Phase 2 Clinical Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2517151082","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517151082?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:50","pubTimestamp":1741265442,"startTime":"0","endTime":"0","summary":"BRIEF-Medicus Pharma Announces Positively Trending Interim Analysis For SKNJCT-003 Phase 2 Clinical Study March 6 (Reuters) - Medicus Pharma Ltd MDCX.O:MEDICUS PHARMA LTD ANNOUNCES POSITIVELY TRENDING","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO1B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2517151864","title":"Medicus Pharma Ltd Announces Positively Trending Interim Analysis for Sknjct-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (Bcc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517151864","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517151864?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264225,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO1B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2517151836","title":"Medicus Pharma: Plans to Submit Analysis to FDA Under Package Seeking Type C Meeting With FDA in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2517151836","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517151836?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264225,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO1B0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2517005159","title":"Medicus Pharma Ltd: D-Mna Was Well Tolerated for Both Dose Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2517005159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517005159?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264225,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO1B0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2517516451","title":"Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517516451","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517516451?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:30","pubTimestamp":1741264200,"startTime":"0","endTime":"0","summary":"The Interim Analysis Showed Complete Clinical Clearance of More Than Sixty (60%) PercentPHILADELPHIA, March  06, 2025  (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (\"Medicus\" or the \"Company","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038085/0/en/Medicus-Pharma-Ltd-Announces-Positively-Trending-Interim-Analysis-for-SKNJCT-003-Phase-2-Clinical-Study-to-Non-Invasively-Treat-Basal-Cell-Carcinoma-of-the-Skin-BCC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","UAE","BK4567","BCC","BK4139","MDCX"],"gpt_icon":0},{"id":"2514279253","title":"Wall Street Set to Open Higher Friday as Inflation Data Meets Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2514279253","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514279253?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:20","pubTimestamp":1740752429,"startTime":"0","endTime":"0","summary":"US stocks looked set to open higher Friday as investors parsed key inflation data that matched analyst forecasts.Dow Jones Industrial Average futures were up 0.49%, S&P 500 futures gained 0.29%, and N","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OCFT","LU0203345920.USD","BTAI","TRNR","DLO","ORGO","BK4106","BK4563","NTAP","BK4585","BK4139","IOVA","BK4023","DCGO","BK4196","MBIO","BK4531","BK4588","BK4227","BK4539","MDCX","SG9999001440.SGD","LU0203347892.USD","BK4170","BK4190"],"gpt_icon":0},{"id":"2514432978","title":"US Stock Futures Rise as Investors Await Key Inflation Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2514432978","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514432978?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:09","pubTimestamp":1740748177,"startTime":"0","endTime":"0","summary":"US stock futures were rising slightly in Friday's premarket activity as investors awaited key inflation and manufacturing data coming out later in the morning.The Dow Jones Industrial Average futures were up 0.4%, S&P 500 futures gained 0.2%, and Nasdaq futures advanced slightly.Oil prices were moving sharply lower, with front-month global benchmarks Brent crude and West Texas Intermediate crude falling 1.2% and 1.4% respectively.The Bureau of Economic Analysis will be releasing monthly and annual core personal consumption expenditure at 8:30 am ET, while the Chicago Purchasing Managers' Index reading for February will come out at 9:45 am ET.In equities, shares of BioXcel Therapeutics  jumped 33% after the company said Friday that it has regained compliance with the Nasdaq Stock Market's minimum closing bid price requirement. Apollomics  shares surged almost 38% following a 3.7% loss Thursday. Shares of Medicus Pharma  advanced 15%, adding to a nearly 12% gain the previous session.On t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UDOW","BK4585","DOG","BK4227",".DJI","PSQ",".IXIC","ISBC","USJW.SI","BK4106","MNQmain","QLD","BK4139","BK4211","USAW.SI","TQQQ","APLM","BK4588","SQQQ","DXD",".SPX","DJX","DCGO","TSYW.SI","MDCX","BTAI","DDM","NQmain","QID","BK4196","NVIW.SI","SDOW","DLO","BK4563","BK4539"],"gpt_icon":1},{"id":"2514804400","title":"Medicus Pharma submits Phase 2 carcinoma clinical design in UAE","url":"https://stock-news.laohu8.com/highlight/detail?id=2514804400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514804400?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:13","pubTimestamp":1740662001,"startTime":"0","endTime":"0","summary":"Medicus Pharma (MDCX) has submitted a clinical design to the United Arab Emirates Department of Health to non-invasively treat Basal Cell Carcinoma...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-phase-2-carcinoma-clinical-design-in-uae?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicus-pharma-submits-phase-2-carcinoma-clinical-design-in-uae?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UAE","BK4139","MDCX"],"gpt_icon":0},{"id":"2514804440","title":"Medicus Pharma Advances Non-Invasive Skin Cancer Treatment in UAE","url":"https://stock-news.laohu8.com/highlight/detail?id=2514804440","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514804440?lang=en_us&edition=fundamental","pubTime":"2025-02-27 21:12","pubTimestamp":1740661927,"startTime":"0","endTime":"0","summary":"The latest update is out from Medicus Pharma Ltd ( ($MDCX) ). Medicus Pharma Ltd has submitted a Phase 2 clinical design to the UAE Department of H...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-advances-non-invasive-skin-cancer-treatment-in-uae?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medicus-pharma-advances-non-invasive-skin-cancer-treatment-in-uae?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UAE","BK4139","MDCX"],"gpt_icon":0},{"id":"2514806809","title":"Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (Sknjct-004) to United Arab Emirates (UAE) Department of Health (Doh) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (Bcc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514806809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514806809?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:31","pubTimestamp":1740659494,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI1BG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2514480990","title":"Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514480990","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514480990?lang=en_us&edition=fundamental","pubTime":"2025-02-27 20:30","pubTimestamp":1740659400,"startTime":"0","endTime":"0","summary":"The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAEPHILADELPHIA, Feb.  27, 2025  (GLOBE NEWSWIRE) -- Medicus Pharma L","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033751/0/en/Medicus-Pharma-Ltd-Announces-Submission-of-Phase-2-Clinical-Design-SKNJCT-004-to-United-Arab-Emirates-UAE-Department-of-Health-DOH-to-Non-Invasively-Treat-Basal-Cell-Carcinoma-of-t.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UAE","BCC","BK4211","BK4567","MDCX","BK4104","UBCP"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744689600000}}}